CY1110085T1 - Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρες - Google Patents
Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρεςInfo
- Publication number
- CY1110085T1 CY1110085T1 CY20101100550T CY101100550T CY1110085T1 CY 1110085 T1 CY1110085 T1 CY 1110085T1 CY 20101100550 T CY20101100550 T CY 20101100550T CY 101100550 T CY101100550 T CY 101100550T CY 1110085 T1 CY1110085 T1 CY 1110085T1
- Authority
- CY
- Cyprus
- Prior art keywords
- testosterone
- kits
- compositions
- combinations
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μορφοποίηση διαδερμικού υδροαλκοολικού ζελέ τεστοστερόνης που ξεπερνά τα προβλήματα που σχετίζονται με άλλους μηχανισμούς διοχέτευσης τεστοστερόνης παρέχοντας, μεταξύ άλλων, επιθυμητό φαρμακοκινητικό προφίλ ορμόνης με μικρό ή κανένα ερεθισμό του δέρματος. Το ζελέ μπορεί να χρησιμοποιηθεί ως μέθοδος βελτίωσης των σεξουαλικών επιδόσεων, συμπεριλαμβανομένων και της θεραπείας της δυσλειτουργίας στύσης και αυξάνοντας τη λίμπιντο, αυξάνοντας τα επίπεδα τεστοστερόνης στους άνδρες. Επιπλέον, το ζελέ μπορεί να χρησιμοποιηθεί σε συνδυασμό με θεραπευτικά που στοχεύουν στη θεραπεία της δυσλειτουργίας στύσης, όπως το VIAGRA®, για να αυξήσουν την αποτελεσματικότητα τους.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/651,777 US6503894B1 (en) | 2000-08-30 | 2000-08-30 | Pharmaceutical composition and method for treating hypogonadism |
US70375300A | 2000-11-01 | 2000-11-01 | |
EP01966486A EP1315502B1 (en) | 2000-08-30 | 2001-08-29 | Method for treating erectile dysfunction and increasing libido in men |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110085T1 true CY1110085T1 (el) | 2015-01-14 |
Family
ID=27096141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100550T CY1110085T1 (el) | 2000-08-30 | 2010-06-15 | Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρες |
Country Status (22)
Country | Link |
---|---|
US (1) | US20050054623A1 (el) |
EP (2) | EP1315502B1 (el) |
JP (1) | JP2004524267A (el) |
KR (1) | KR100861603B1 (el) |
CN (1) | CN1473047A (el) |
AT (1) | ATE460939T1 (el) |
AU (2) | AU8699501A (el) |
BR (1) | BR0113651A (el) |
CA (2) | CA2420895C (el) |
CY (1) | CY1110085T1 (el) |
DE (1) | DE60141587D1 (el) |
DK (1) | DK1315502T3 (el) |
ES (1) | ES2341090T3 (el) |
IL (1) | IL154692A0 (el) |
MX (1) | MXPA03001858A (el) |
NO (1) | NO332649B1 (el) |
NZ (1) | NZ524601A (el) |
PL (1) | PL205279B1 (el) |
PT (1) | PT1315502E (el) |
SI (1) | SI1315502T1 (el) |
TR (1) | TR200300776T2 (el) |
WO (1) | WO2002017927A1 (el) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
JP5039252B2 (ja) * | 2000-08-31 | 2012-10-03 | ユニメッド ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 性機能低下を治療するための医薬組成物及び方法 |
MY139721A (en) | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
AUPS317302A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Metastable pharmaceutical compositions |
BRPI0312007B1 (pt) | 2002-06-25 | 2015-04-14 | Acrux Dds Pty Ltd | Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição |
IL152573A (en) | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
IL152575A (en) | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
RS52945B (en) | 2004-05-11 | 2014-02-28 | Emotional Brain B.V. | PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
ES2607454T3 (es) | 2005-06-03 | 2017-03-31 | Acrux Dds Pty Ltd | Método y composición para el suministro transdérmico de testosterona |
MX2007015255A (es) * | 2005-06-03 | 2008-02-22 | Acrux Dds Pty Ltd | Metodo y composicion para administracion transdermica de un farmaco. |
US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
BRPI0617294B8 (pt) | 2005-10-12 | 2021-05-25 | Besins Healthcare Lu Sarl | composição farmacêutica em gel hidroalcóolico e uso de testosterona |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
US8613360B2 (en) | 2006-09-29 | 2013-12-24 | M-I L.L.C. | Shaker and degasser combination |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
GB2461725B (en) | 2008-07-10 | 2012-06-13 | United Wire Ltd | Improved sifting screen |
US20100022497A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject |
US20100022494A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
US20100022487A1 (en) * | 2008-07-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
US20110190201A1 (en) * | 2008-07-24 | 2011-08-04 | Searete Llc | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
WO2011140635A2 (en) | 2010-05-12 | 2011-11-17 | Daniel Guy Pomerleau | Systems and methods for drying drill cuttings |
RU2474424C2 (ru) * | 2010-09-24 | 2013-02-10 | Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин |
EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
US9795639B1 (en) * | 2013-03-16 | 2017-10-24 | BioDlogics, LLC | Methods for the treatment of erectile dysfunction by human birth tissue material compostion |
US8785426B1 (en) | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
WO2019152854A1 (en) * | 2018-02-02 | 2019-08-08 | Aytu Bioscience, Inc. | Methods of testosterone therapy |
AU2020379828A1 (en) | 2019-11-06 | 2022-04-28 | Smartech Topical, Inc. | Topical formulations of cyclooxygenase inhibitors and their use |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
US4855305A (en) * | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
TW224048B (el) * | 1992-03-30 | 1994-05-21 | Hoechst Roussel Pharma | |
DE69326461T2 (de) * | 1992-06-11 | 2000-05-04 | Theratech Inc., Salt Lake City | Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung |
US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
JP4036496B2 (ja) * | 1995-10-24 | 2008-01-23 | リンテック株式会社 | ゲル製剤の製造方法 |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5730987A (en) * | 1996-06-10 | 1998-03-24 | Omar; Lotfy Ismail | Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
WO1998034621A1 (en) * | 1997-02-07 | 1998-08-13 | Theratech, Inc. | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
IL136042A (en) * | 1997-11-10 | 2005-12-18 | Cellegy Pharma Inc | Alcohol-containing composition for topical application |
ATE303774T1 (de) * | 1998-06-25 | 2005-09-15 | Lavipharm Lab Inc | Vorrichtung und verfahren zur behandlung von erektionsstörungen |
JP2000225116A (ja) * | 1998-12-04 | 2000-08-15 | Eisai Co Ltd | 陰茎径の測定法 |
JP2000212080A (ja) * | 1999-01-26 | 2000-08-02 | Hiroshi Azuma | ***機能不全改善剤 |
DE19903087A1 (de) * | 1999-01-27 | 2000-08-10 | Forssmann Wolf Georg | Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern |
DE60006069T2 (de) * | 1999-02-05 | 2004-07-29 | Cipla Ltd. | Topische sprays enthaltend eine filmbildende zusammensetzung |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
-
2001
- 2001-08-29 NZ NZ524601A patent/NZ524601A/en not_active IP Right Cessation
- 2001-08-29 JP JP2002522900A patent/JP2004524267A/ja active Pending
- 2001-08-29 AT AT01966486T patent/ATE460939T1/de active
- 2001-08-29 ES ES01966486T patent/ES2341090T3/es not_active Expired - Lifetime
- 2001-08-29 PT PT01966486T patent/PT1315502E/pt unknown
- 2001-08-29 KR KR1020037003148A patent/KR100861603B1/ko active IP Right Grant
- 2001-08-29 BR BR0113651-8A patent/BR0113651A/pt not_active Application Discontinuation
- 2001-08-29 MX MXPA03001858A patent/MXPA03001858A/es active IP Right Grant
- 2001-08-29 PL PL366037A patent/PL205279B1/pl unknown
- 2001-08-29 AU AU8699501A patent/AU8699501A/xx active Pending
- 2001-08-29 TR TR2003/00776T patent/TR200300776T2/xx unknown
- 2001-08-29 SI SI200130964T patent/SI1315502T1/sl unknown
- 2001-08-29 EP EP01966486A patent/EP1315502B1/en not_active Expired - Lifetime
- 2001-08-29 CN CNA018172660A patent/CN1473047A/zh active Pending
- 2001-08-29 DK DK01966486.1T patent/DK1315502T3/da active
- 2001-08-29 DE DE60141587T patent/DE60141587D1/de not_active Expired - Lifetime
- 2001-08-29 CA CA002420895A patent/CA2420895C/en not_active Expired - Lifetime
- 2001-08-29 WO PCT/US2001/027205 patent/WO2002017927A1/en active Application Filing
- 2001-08-29 EP EP10184108A patent/EP2283865A1/en not_active Withdrawn
- 2001-08-29 AU AU2001286995A patent/AU2001286995B2/en not_active Expired
- 2001-08-29 IL IL15469201A patent/IL154692A0/xx active IP Right Grant
- 2001-08-29 CA CA2746787A patent/CA2746787A1/en not_active Abandoned
-
2003
- 2003-02-28 NO NO20030955A patent/NO332649B1/no not_active IP Right Cessation
-
2004
- 2004-02-25 US US10/787,071 patent/US20050054623A1/en not_active Abandoned
-
2010
- 2010-06-15 CY CY20101100550T patent/CY1110085T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1315502T1 (sl) | 2010-07-30 |
CN1473047A (zh) | 2004-02-04 |
NO20030955D0 (no) | 2003-02-28 |
BR0113651A (pt) | 2004-11-09 |
CA2746787A1 (en) | 2002-03-07 |
KR20030043949A (ko) | 2003-06-02 |
DK1315502T3 (da) | 2010-07-19 |
MXPA03001858A (es) | 2004-05-21 |
EP1315502A1 (en) | 2003-06-04 |
NO20030955L (no) | 2003-04-28 |
EP1315502B1 (en) | 2010-03-17 |
JP2004524267A (ja) | 2004-08-12 |
AU8699501A (en) | 2002-03-13 |
CA2420895A1 (en) | 2002-03-07 |
TR200300776T2 (tr) | 2005-10-21 |
ATE460939T1 (de) | 2010-04-15 |
WO2002017927A1 (en) | 2002-03-07 |
PT1315502E (pt) | 2010-05-06 |
NZ524601A (en) | 2006-04-28 |
EP2283865A1 (en) | 2011-02-16 |
AU2001286995B2 (en) | 2006-11-30 |
PL366037A1 (en) | 2005-01-24 |
US20050054623A1 (en) | 2005-03-10 |
CA2420895C (en) | 2007-03-13 |
NO332649B1 (no) | 2012-11-26 |
DE60141587D1 (de) | 2010-04-29 |
ES2341090T3 (es) | 2010-06-15 |
KR100861603B1 (ko) | 2008-10-07 |
PL205279B1 (pl) | 2010-03-31 |
IL154692A0 (en) | 2003-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110085T1 (el) | Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρες | |
MXPA03001859A (es) | Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados. | |
Haynes et al. | The pharmacology of letrozole | |
BR0316203A (pt) | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica | |
BR0215254A (pt) | Composições e métodos para intensificar a liberação de corticoesteróides | |
GB0001449D0 (en) | Compositions | |
BR9916518A (pt) | Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos | |
DE69833971D1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
CL2004000026A1 (es) | Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino. | |
BR9807828A (pt) | Composições e método para a suplementação de testosterona em mulheres com sintomas de deficiência de testosterona | |
Kruithof-Dekker et al. | Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy | |
BR0110208A (pt) | Composições e terapias para distúrbios associados com hiperlipidemia | |
BR0114665A (pt) | Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio | |
WO2002039994A3 (en) | Methods for the treatment and prevention of urinary stone disease | |
EA200401210A1 (ru) | Андрогенная фармацевтическая композиция и способ для лечения депрессии | |
BR0214643A (pt) | Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite | |
HUP9901505A2 (hu) | Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására | |
BR0109789A (pt) | Método para o tratamento de câncer de mama, e, uso de fulvestrante | |
BR0213162A (pt) | Métodos para prevenção e tratamento da perda óssea com compostos esteróides | |
MX2020011341A (es) | Una composicion para el tratamiento de una o mas enfermedades relacionadas con los estrogenos. | |
Carlström et al. | Peripheral androgen levels in danazol-treated premenopausal women | |
WO2002039995A3 (en) | Combination therapy for estrogen-dependent disorders | |
AR038904A1 (es) | Metodo para incrementar en la mujer las concentraciones de testosterona y esteroides relacionados | |
HK1060135A1 (en) | 4-Halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
AR032371A1 (es) | Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas |